Polymorphisms for GSTP-1, ERCC1 and XRCC1 have been previously identified as potential predictive biomarker for platinum based chemotherapy in colon cancer patients 34, 35, 40, 41. Here, ERCC1 is linked to malignant colon neoplasm.